In 2020, there were more than 1,350 medical conferences in the United States alone, and 447 of them focused on oncology.
With more events popping up in every corner of the world, and the option to attend virtually for many, how can you develop the best conference calendar for what remains of 2021?
Our team of experts put together a list of the top 100 oncology conferences happening in 2021, organized in an easy-to-reference calendar view.
We’ve done even more analysis to identify the top 5 events. Our ranking criteria considered the focus of the conference, the number of abstracts expected, and the attendance of past meetings.
Once you’ve identified your own Top 10, LARVOL can help you maximize your attendance.
LARVOL CONF planners will bring you the information you need when you need it! Our analysts review and manually curate each conference’s abstracts and titles as soon as they’re released and deliver a straightforward spreadsheet tool outlining all sessions, abstracts, identified diseases, products, and mechanisms of action (MOAs).
With the CONF planner, you’ll get the latest facts at each stage of the conference:
Download our conference list here and click here to request your LARVOL CONF planner.
In addition to planning ahead for upcoming conferences, it's also important to reflect on the data presented and it's impact on the standard-of-care. LARVOL hosts live, 30-minute panel interviews immediately following major oncology conferences. These panels consist of key opinion leaders (KOLs) and experts in the cancer type at hand discussing 2-3 abstracts, moderated by a LARVOL expert in cancer research.
These conversations present a unique opportunity to further the scientific discussion around new scientific data and are a valuable source of insight into the opinions of experts on the treatments covered in the abstracts.
LARVOL Panel Series are planned for the following oncology conferences in 2021:
Contact us for more information on these events and download your list of the top 100 oncology conferences for 2021!
To request a demo of VIEW visit here.
79% had reduction in disease. ORR 31%. Many responses deepen over time.
Toxicity profile was in line with prior TIL/Lifileucel data. No surprises here. Median # doses of IL-2 was 6.
Absolutely agree!… this should be available to our melanoma patients ASAP!… and paves the way for smarter cellular therapies to be designed, studied, and eventually widely disseminated
Just before I start AM clinic at @cityofhopeoc, excited to share results from #COBALT_RCC, a P1 trial of @CRISPRTX#CTX130 in #kidneycancer in the @sitcancer#PressProgram. Will present more on Thurs 5:37p at #SITC22! Thx @neerajaiims@DrBenTran@HaanenJohn#SamerSrour& co-Is! t.co/aDnhG9n92A
@montypal@cityofhopeoc@CRISPRTX@sitcancer@neerajaiims@DrBenTran@HaanenJohn@DrChoueiri@TiansterZhang@tompowles1@brian_rini@AlbigesL@Uromigos@ERPlimackMD@drenriquegrande@PGrivasMDPhD Congrats Monty! Looking forward to hearing about this exciting first-in the field study!
CAR-Ts are coming for #kidneycancer!! Congratulations @montypal and team; can’t wait to see results at #SITC22! t.co/9MrlF2yzBe
Congrats @montypal and team! Great to see CAR T therapy coming to #RCCt.co/ypRHBC89Pt
Another huge step from none other than @montypal!! CAR-Ts in #kidneycancer!Congratulations to the entire team!Looking forward to seeing the results at #SITC22! t.co/HvKeVBPyV7
@montypal you never stop to amaze me! You are brilliant & awesome! Looking forward to hearing more about this trial @sitcancer@OncoAlert@CityofHope_GU@COHMDCareers@neerajaiims@KidneyCancer@KidneyCancerDoc@NazliDizman@ZeynepZengin@LuisMezaco@crisbergerot@PauloBergerott.co/RNzOwxixQm
Primary results from the randomized Phase II RIGHT Choice trial of premenopausal patients with aggressive HR+/HER2− advanced breast cancer treated with ribociclib + endocrine therapy vs physician’s choice combination chemotherapy
Efficacy and Safety of Ibrutinib Combined with Standard First-Line Treatment or As Substitute for Autologous Stem Cell Transplantation in Younger Patients with Mantle Cell Lymphoma: Results from the Randomized Triangle Trial By the European MCL Network